BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21707361)

  • 1. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
    Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
    Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
    Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.
    Casnici C; Crotta K; Volpe G; Panuzzo C; Lattuada D; Mesiano G; Saglio G; Marelli O
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):149-156. PubMed ID: 28704165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.
    van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
    Leukemia; 1994 Sep; 8(9):1503-9. PubMed ID: 8090030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
    van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
    Leukemia; 1992 Nov; 6(11):1107-12. PubMed ID: 1434792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preparation and characterization of the monoclonal antibodies to PTD-bcr/abl].
    Chen RA; Liu L; Jiang SS; Liang YM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 May; 24(5):488-90. PubMed ID: 18466710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
    Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
    Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications].
    Zhu HH; Liu YR; Qin YZ; Chang Y; Li JL; Ruan GR; Jiang B; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):441-4. PubMed ID: 17147244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.
    Wada H; Mizutani S; Nishimura J; Usuki Y; Kohsaki M; Komai M; Kaneko H; Sakamoto S; Delia D; Kanamaru A
    Cancer Res; 1995 Jul; 55(14):3192-6. PubMed ID: 7606740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.